We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 06, 2021

Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-Type Metastatic Colorectal Cancer

JAMA Oncology


Additional Info

JAMA Oncology
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial
JAMA Oncol 2021 Oct 01;7(10)1529-1535, E Martinelli, G Martini, V Famiglietti, T Troiani, S Napolitano, F Pietrantonio, D Ciardiello, M Terminiello, C Borrelli, PP Vitiello, F De Braud, F Morano, A Avallone, N Normanno, A Nappi, E Maiello, T Latiano, A Falcone, C Cremolini, D Rossini, G Santabarbara, C Pinto, D Santini, C Cardone, N Zanaletti, A Di Liello, D Renato, L Esposito, F Marrone, F Ciardiello

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading